72 related articles for article (PubMed ID: 19145672)
41. [Combination chemotherapy of doxifluridine plus mitomycin C for colorectal lung metastasis--phase II study].
Ike H; Sadahiro S; Oya K; Otani Y; Shimada H; Yamaguchi S; Hiki Y; Fujita H; Mitomi T;
Gan To Kagaku Ryoho; 2001 Sep; 28(9):1263-8. PubMed ID: 11579637
[TBL] [Abstract][Full Text] [Related]
42. Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study.
Salgado M; Reboredo M; Mendez JC; Quintero G; Pellón ML; Romero C; Jorge M; Montes AF; Valladares-Ayerbes M; Ramos M; Varela S; Alonso MÁ;
Anticancer Res; 2013 Sep; 33(9):4089-96. PubMed ID: 24023354
[TBL] [Abstract][Full Text] [Related]
43. Mitomycin-C+fluoropyrimidines in heavily pretreated metastatic colorectal cancer: a systematic review and evidence synthesis.
Petrelli F; Ghidini A; Inno A; Barni S
Anticancer Drugs; 2016 Jul; 27(6):488-95. PubMed ID: 27186954
[TBL] [Abstract][Full Text] [Related]
44. Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.
Ntukidem N; Arce-Lara C; Otterson GA; Kraut E; Cataland S; Bekaii-Saab T
Cancer Chemother Pharmacol; 2010 Jan; 65(2):319-24. PubMed ID: 19506871
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Abbasi S; Kashashna A; Albaba H
Pancreas; 2014 Nov; 43(8):1303-5. PubMed ID: 25036906
[TBL] [Abstract][Full Text] [Related]
46. [Three cases of colorectal cancer with lung metastasis successfully treated with combination chemotherapy using 5'-DFUR and MMC].
Hosoya Y; Konishi H; Horie H; Ishizuka T; Shitou K; Kojima M; Kashiwagi H; Kanazawa K
Gan To Kagaku Ryoho; 1998 Sep; 25(11):1761-5. PubMed ID: 9757203
[TBL] [Abstract][Full Text] [Related]
47. [Mitomycin C plus HCFU adjuvant chemotherapy for noncuratively resected cases of colorectal carcinoma. (Second report): 5-year survival rate. Cooperative Study Group of Kyushu and Chugoku for HCFU Adjuvant Chemotherapy].
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):333-9. PubMed ID: 2494948
[TBL] [Abstract][Full Text] [Related]
48. Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer.
Mullin G; Sternschuss M; Landman Y; Sulkes A; Brenner B
World J Gastrointest Oncol; 2023 Nov; 15(11):1913-1924. PubMed ID: 38077638
[TBL] [Abstract][Full Text] [Related]
49. Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer.
Ito K; Yamaguchi A; Miura K; Kato T; Koike A; Takagi H
J Surg Oncol; 1996 May; 62(1):4-9. PubMed ID: 8618399
[TBL] [Abstract][Full Text] [Related]
50. Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer.
Dees A; Verweij J; van Putten WL; Stoter G
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1343-7. PubMed ID: 3119346
[TBL] [Abstract][Full Text] [Related]
51. Mitomycin-C and lonidamine as second-line therapy for colorectal cancer: a phase II study.
Zaniboni A; Meriggi F; Alghisi A; Mutti S; Distefano L; Rizzi A; Bettini L; Simoncini E; Marpicati P; Montini E
Tumori; 1995; 81(6):435-7. PubMed ID: 8804471
[TBL] [Abstract][Full Text] [Related]
52. 5-Fluorouracil and mitomycin-C in colorectal cancer: unacceptable conclusion.
Herrmann R
Ann Oncol; 1998 Mar; 9(3):342. PubMed ID: 9714583
[No Abstract] [Full Text] [Related]
53. 5-Fluorouracil and mitomycin-C in colorectal cancer: unacceptable conclusion.
Herrmann R
Ann Oncol; 1998 Feb; 9(2):230. PubMed ID: 9553673
[No Abstract] [Full Text] [Related]
54. Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients.
Gabizon AA; Tahover E; Golan T; Geva R; Perets R; Amitay Y; Shmeeda H; Ohana P
Invest New Drugs; 2020 Oct; 38(5):1411-1420. PubMed ID: 31955309
[TBL] [Abstract][Full Text] [Related]
55. Second line chemotherapy for metastatic colorectal carcinoma.
Gebbia V; Testa A; Cannata G; Tirrito M; Longo A; Sciume C; Valdesi M; Salamone G; Gebbia N; Leo P
Oncol Rep; 1996 Sep; 3(5):867-9. PubMed ID: 21594470
[TBL] [Abstract][Full Text] [Related]
56. [Cross-Functional Project of Using Information-Sharing Tool for Metastatic Colorectal Cancer Patients in University Hospital].
Nomura K; Kuribayashi M; Yarimizu A; Hirata M; Nishimura Y; Kimura K; Takenaka Y; Son C; Babaya A; Beppu N; Uchino M; Ikeuchi H; Ikeda M; Kataoka K
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1718-1720. PubMed ID: 35046308
[TBL] [Abstract][Full Text] [Related]
57. Chemotherapeutic outcomes for metastatic colorectal cancer in elderly patients aged ≥75 years: A single-institutional retrospective analysis.
Miguchi M; Shimomura M; Hinoi T; Egi H; Ohdan H
Asia Pac J Clin Oncol; 2016 Jun; 12(2):151-8. PubMed ID: 26969020
[No Abstract] [Full Text] [Related]
58. Treatment regimen for metastatic colorectal cancer.
Leake I
Nat Rev Gastroenterol Hepatol; 2019 Dec; 16(12):706. PubMed ID: 31659264
[No Abstract] [Full Text] [Related]
59. Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.
Arnold D; Prager GW; Quintela A; Stein A; Moreno Vera S; Mounedji N; Taieb J
Ann Oncol; 2018 Apr; 29(4):835-856. PubMed ID: 29452346
[TBL] [Abstract][Full Text] [Related]
60. Capecitabine and mitomycin-C in the therapy of pretreated patients with metastatic colorectal cancer: single center retrospective study with 36 patients.
Vrdoljak E; Omrcen T; Boban M; Hrepic D
J BUON; 2008; 13(4):513-8. PubMed ID: 19145672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
